|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
D'Augè TG, Di Donato V and Giannini A:
Strategic approaches in management of early-stage cervical cancer:
A comprehensive editorial. Clin Exp Obstet Gynecol. 51:235–237.
2024.
|
|
3
|
Ferlay J, Ervik M, Lam F, Colombet M, Mery
L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global cancer
observatory: Cancer today. Available from: https://gco.iarc.fr/today (open in a new window).
Accessed January 2, 2020.
|
|
4
|
Meng Y, Chu T, Lin S and Wu P, Zhi W, Peng
T, Ding W, Luo D and Wu P: Clinicopathological characteristics and
prognosis of cervical cancer with different histological types: A
population-based cohort study. Gynecol Oncol. 163:545–551.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mohamud A, Høgdall C and Schnack T:
Prognostic value of the 2018 FIGO staging system for cervical
cancer. Gynecol Oncol. 165:506–513. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
D'Oria O, Bogani G, Cuccu I, D'Auge TG, Di
Donato V, Caserta D and Giannini A: Pharmacotherapy for the
treatment of recurrent cervical cancer: An update of the
literature. Expert Opin Pharmacother. 25:55–65. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shao Y, Gui X, Wang Y, Sheng L, Sun D,
Zeng Q and Wang H: Serum soluble immune checkpoint levels predict
cervical lymph node metastasis of differentiated thyroid carcinoma
patients. Cancer Med. 12:17648–17659. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cedeno-Laurent F and Dimitroff CJ:
Galectins and their ligands: Negative regulators of antitumor
immunity. Glycoconj J. 29:619–625. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ohue Y, Kurose K, Nozawa R, Isobe M,
Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M and Nakayama
E: Survival of lung adenocarcinoma patients predicted from
expression of PD-L1, galectin-9, and XAGE1 (GAGED2a) on tumor cells
and tumor-infiltrating T cells. Cancer Immunol Res. 4:1049–1060.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li J, Sun XF, Shen Y, Yang Q and Dai SY:
Elevated expression of T-cell immunoglobulin and mucin domain 3 on
T cells from peripheral blood in patients with cervical carcinoma.
Gynecol Obstet Invest. 86:63–70. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang
L, Huang M and Zhou J: Tim-3 expression in cervical cancer promotes
tumor metastasis. PLoS One. 8(e53834)2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen Z, Dong D, Zhu Y, Pang N and Ding J:
The role of Tim-3/Galectin-9 pathway in T-cell function and
prognosis of patients with human papilloma virus-associated
cervical carcinoma. FASEB J. 35(e21401)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gu D, Ao X, Yang Y, Chen Z and Xu X:
Soluble immune checkpoints in cancer: Production, function and
biological significance. J Immunother Cancer. 6(132)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Khan M, Arooj S and Wang H: Soluble
B7-CD28 family inhibitory immune checkpoint proteins and
anti-cancer immunotherapy. Front Immunol. 12(651634)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Geng H, Zhang GM, Li D, Zhang H, Yuan Y,
Zhu HG, Xiao H, Han LF and Feng ZH: Soluble form of T cell Ig mucin
3 is an inhibitory molecule in T cell-mediated immune response. J
Immunol. 176:1411–1420. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hansen JA, Hanash SM, Tabellini L, Baik C,
Lawler RL, Grogan BM, Storer B, Chin A, Johnson M, Wong CH, et al:
A novel soluble form of Tim-3 associated with severe
graft-versus-host disease. Biol Blood Marrow Transplant.
19:1323–1330. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Möller-Hackbarth K, Dewitz C, Schweigert
O, Trad A, Garbers C, Rose-John S and Scheller J: A disintegrin and
metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell
immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem.
288:34529–34544. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li F, Li N, Sang J, Fan X, Deng H, Zhang
X, Han Q, Lv Y and Liu Z: Highly elevated soluble Tim-3 levels
correlate with increased hepatocellular carcinoma risk and poor
survival of hepatocellular carcinoma patients in chronic hepatitis
B virus infection. Cancer Manag Res. 10:941–951. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lu K, Ma H, Wang T, Huang Y and Ru M: The
diagnostic value of soluble TIM-3 in oral squamous cell carcinoma.
Future Oncol. 18:1381–1390. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Peng Y, Zhang C, Rui Z, Tang W, Xu Y, Tao
X, Zhao Q and Tong X: A comprehensive profiling of soluble immune
checkpoints from the sera of patients with non-small cell lung
cancer. J Clin Lab Anal. 36(e24224)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rapoport BL, Steel HC, Benn CA, Nayler S,
Smit T, Heyman L, Theron AJ, Hlatshwayo N, Kwofie LLI, Meyer PWA
and Anderson R: Dysregulation of systemic soluble immune
checkpoints in early breast cancer is attenuated following
administration of neoadjuvant chemotherapy and is associated with
recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially
increased levels of PD-L1, LAG-3 and TIM-3. Front Oncol.
13(1097309)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu C, Li X, Li A, Zou W, Huang R, Hu X,
Yu J, Zhang X and Yue J: Concurrent chemoradiotherapy Increases the
levels of soluble immune checkpoint proteins in patients with
locally advanced cervical cancer. J Immunol Res.
2022(9621466)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Reyes-Vallejo T, Conde-Rodríguez I,
Serna-Villalobos J, Ramírez-Díaz I, Pérez-Villalobos G,
Delgado-López G, Vazquez-Zamora VJ, Gutiérrez-Quiroz CT,
Ávila-Jiménez L, García-Carrancá A, et al: Serum levels of
galectin-9 are increased in cervical cancer patients and are higher
in advanced clinical stages. Onco Targets Ther. 15:1211–1220.
2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nayar R and Wilbur DC: The bethesda system
for reporting cervical cytology: A historical perspective. Acta
Cytol. 61:359–372. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
DeLong ER, DeLong DM and Clarke-Pearson
DL: Comparing the areas under two or more correlated receiver
operating characteristic curves: A nonparametric approach.
Biometrics. 44:837–845. 1988.PubMed/NCBI
|
|
26
|
Bailly C, Thuru X, Goossens L and Goossens
JF: Soluble TIM-3 as a biomarker of progression and therapeutic
response in cancers and other of human diseases. Biochem Pharmacol.
209(115445)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Malinga NZ, Siwele SC, Steel HC, Kwofie
LLI, Meyer PWA, Smit T, Anderson R, Rapoport BL and Kgokolo MCM:
Systemic levels of the soluble co-inhibitory immune checkpoints,
CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal
cell carcinoma. Transl Oncol. 19(101384)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hong J, Chen X, Chen L, Wang Y, Huang B
and Fang H: Clinical value of combined detection of serum sTim-3
and CEA or CA19-9 for postoperative recurrence of colorectal cancer
diagnosis. Cancer Manag Res. 15:563–572. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen L, Hong J, Hu R, Yu X, Chen X, Zheng
S, Qin Y, Zhou X, Wang Y, Zheng L, et al: Clinical value of
combined detection of serum sTim-3 and pepsinogen for gastric
cancer diagnosis. Cancer Manag Res. 13:7759–7769. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li B, Wang Q, Luo Y, Wang S, Pan S, Zhao
W, Ye Z and Wu X: Peripheral soluble immune checkpoint-related
proteins were associated with survival and treatment efficacy of
osteosarcoma patients, a cohort study. Cancers (Basel).
16(1628)2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang Q, Zhang J, Tu H, Liang D, Chang DW,
Ye Y and Wu X: Soluble immune checkpoint-related proteins as
predictors of tumor recurrence, survival, and T cell phenotypes in
clear cell renal cell carcinoma patients. J Immunother Cancer.
7(334)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen C, Zhao F, Peng J, Zhao D, Xu L, Li
H, Ma S, Peng X, Sheng X, Sun Y, et al: Soluble Tim-3 serves as a
tumor prognostic marker and therapeutic target for CD8+ T cell
exhaustion and anti-PD-1 resistance. Cell Rep Med.
5(101686)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yasinska IM, Sakhnevych SS, Pavlova L,
Selnø AT, Abeleira AM, Benlaouer O, Silva IG, Mosimann M, Varani L,
Bardelli M, et al: The Tim-3-Galectin-9 pathway and its regulatory
mechanisms in human breast cancer. Front Immunol.
10(1594)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Müllerová M, Hovorková M, Závodná T, Št
Astná LC, Krupková A, Hamala V, Nováková K, Topinka J, Bojarová P
and Strašák T: Lactose-functionalized carbosilane glycodendrimers
are highly potent multivalent ligands for Galectin-9 binding:
Increased glycan affinity to galectins correlates with aggregation
behavior. Biomacromolecules. 24:4705–4717. 2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
36
|
Yang R, Sun L, Li CF, Wang YH, Yao J, Li
H, Yan M, Chang WC, Hsu JM, Cha JH, et al: Galectin-9 interacts
with PD-1 and TIM-3 to regulate T cell death and is a target for
cancer immunotherapy. Nat Commun. 12(832)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lake CM, Voss K, Bauman BM, Pohida K,
Jiang T, Dveksler G and Snow AL: TIM-3 drives temporal differences
in restimulation-induced cell death sensitivity in effector CD8+ T
cells in conjunction with CEACAM1. Cell Death Dis.
12(400)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Smith CM, Li A, Krishnamurthy N and Lemmon
MA: Phosphatidylserine binding directly regulates TIM-3 function.
Biochem J. 478:3331–3349. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang J, Li H, Kulkarni A, Anderson JL,
Upadhyay P, Onyekachi OV, Arantes LMRB, Banerjee H, Kane LP, Zhang
X, et al: Differential impact of TIM-3 ligands on NK cell function.
J Immunother Cancer. 13(e010618)2025.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yim EK and Park JS: Biomarkers in cervical
cancer. Biomark Insights. 1:215–225. 2007.PubMed/NCBI
|
|
41
|
Chen W, Xiu S, Xie X, Guo H, Xu Y, Bai P
and Xia X: Prognostic value of tumor measurement parameters and
SCC-Ag changes in patients with locally-advanced cervical cancer.
Radiat Oncol. 17(6)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fu J, Wang W, Wang Y, Liu C and Wang P:
The role of squamous cell carcinoma antigen (SCC Ag) in outcome
prediction after concurrent chemoradiotherapy and treatment
decisions for patients with cervical cancer. Radiat Oncol.
14(146)2019.PubMed/NCBI View Article : Google Scholar
|
